Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

.

About Teriflunomide

Teriflunomide is a new oral disease modifier for RMS that blocks de novo pyrimidine synthesis thus reducing T- and B-cells proliferation with no cytotoxicity. A comprehensive clinical development program for teriflunomide has been launched in monotherapy. First Phase II study results of the safety and efficacy of teriflunomide monotherapy in MS were published in Neurology in 2006. In addition to the TEMSO trial, two other Phase III trials, TOWER and TENERE, are ongoing in RMS. A Phase III study, TOPIC, is also underway in early MS or Clinically Isolated Syndrome (CIS). Teriflunomide has also been evaluated as an adjunct therapy to either interferon 1-beta or glatiramer acetate in two Phase II studies. Results of these studies were presented earlier this year during the American Committee for Treatment and Research in Multiple Sclerosis meeting (ACTRIMS) congress, and the American Academy of Neurology (AAN) meeting respectively. Phase II studies with teriflunomide (7mg and 14mg) in adjunct with interferon 1-beta demonstrated an improvement in outcomes, with a consistent safety profile in patients treated with the adjunct treatment compared with patients treated with IFN-beta and receiving placebo. In the other Phase II study, teriflunomide in adjunct to glatiramer acetate (GA) was well-tolerated compared to patients receiving GA and placebo. Although there was a numerical trend for the reduction in number and volume of gadolinium enhancing T-1 brain MRI lesions in the adjunct arm compared to placebo with GA, the relative effect was not as robust as that observed for teriflunomide with IFN-beta.

About TEMSO Study

TEMSO is a 2-year randomized, double-blind, placebo controlled study including 1088 RMS patients worldwide, aged 18-55 years, with an Expanded Disability Status Scale (EDSS) <= 5.5 and at least one relapse over the previous year or at least 2 relapses over the preceding 2 years. Patients were randomized
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Regenestem Network has announced the grand opening ... Argentina. The clinic will be lead by Silvina Pastrana, ... a multidisciplinary team of medical professionals who specialize in ... office. , The new Regenestem Network members plan ... in cellular therapies, and establish Regenestem protocols to isolate ...
(Date:5/26/2015)... , May 26, 2015  Sangamo BioSciences, Inc. (NASDAQ: ... Sangamo,s president and CEO, will provide an update on the ... an overview of the company,s business strategy at 1:30pm ET ... Healthcare Conference. The conference is being held in ... be webcast live and may be accessed via a link ...
(Date:5/26/2015)... Parsippany, NJ (PRWEB) May 26, 2015 ... quality balances and scales, is set to release a ... Portfolio of quality-driven laboratory instruments. For over a century, ... reliability in weighing technology throughout the world. Now ... that has gone Beyond Weighing to include water quality ...
(Date:5/26/2015)... , 26. mája 2015 ... mene svojej rodiny prezidentom Barackovi Obamovi a Billovi ... súvislosti so stratou Dr. Rongxiang Xu , ... http://photos.prnewswire.com/prnh/20150522/218111 Dr. Xu bol pionier, ... a jeho odhodlanie v oblasti vedy a príkladné ...
Breaking Biology Technology:Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2OHAUS Corporation to Release New Water Analysis Meters in 2015 2OHAUS Corporation to Release New Water Analysis Meters in 2015 3Dr. Rongxiang Xu, O legende 2
... July 26 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) will ... Thursday, August 5, 2010 at 4:30 p.m. Eastern time ... , , ... States ) or (707) 287-9361 (International). In addition, the call will be webcast ...
... and TORONTO , July 26 ... testing in clinical research and diagnostics, has acquired Xceed Molecular, ... Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The ... of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, ...
... SHANGHAI , July 23 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,("China-Biotics", ... probiotics products in China , today announced,it will host a conference ... 9, 2010 to discuss the fiscal year 2011 first quarter financial ... , , ...
Cached Biology Technology:Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine 2Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine 3Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine 4China-Biotics to Report Fiscal Year 2011 First Quarter Financial Results on August 9 2
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an order for ... World Peace Industrial Group (WPI), part of WPG Holdings. WPI ... . Deliveries are planned to take place during Q3 2015 ... China . The order value of 235 ... 1 000 MSEK for 2015.   Jörgen Lantto, acting ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... BioMed Central and Wilfrid Laurier University today announce ... that provides a visible point of open access ... the University community. Built on BioMed ... extensive open access knowledge and technology experience, Laurier ...
... the mice the researchers found alterations which may be closely ... of an international study led by the Leipzig Max Planck ... the current issue of the renowned journal Cell . ... Mnchen have generated and analyzed a mouse model in which ...
... Technology, an award-winning biometric technology research and development ... leader in workforce management solutions, has chosen M2SYS ... solution that seamlessly interfaces with Kronos time and ... fingerprint and finger vein identification, enabling Kronos customers ...
Cached Biology News:'Canadian excellence' strengthened by extensive adoption of open access 2Mouse model provides clues to human language development 2M2SYS Technology to Offer Desktop Biometric Technology to Kronos Customers 2
... The ELx50 is a fast and versatile ... with our patented Dual-ActionTM 16-channel manifold. This ... the dispense and aspiration manifolds for overfill ... and 384-well formats. The problem of fitting ...
... Schistosomal glutathione-S-transferase (GST) is commonly used as ... E. coli (1). The GSTTag sequence has ... in some cases the solubility of its ... properly folded form, GSTTag fusion proteins can ...
... 1200L sets the new standard for ... incorporating the latest technologies and providing ... analytical needs. The Atmospheric Pressure ... Quadrupole Analyzer provide superior selectivity and ...
Polio component type I...
Biology Products: